Viewing Study NCT01851551


Ignite Creation Date: 2025-12-24 @ 11:40 PM
Ignite Modification Date: 2026-04-16 @ 4:54 PM
Study NCT ID: NCT01851551
Status: COMPLETED
Last Update Posted: 2020-01-03
First Post: 2013-04-29
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
Sponsor: Acrotech Biopharma Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module